Bolt Biotherapeutics (BOLT)

• Market cap: $7.97M
• 1 day: -3.71%
• 5 days: -9.39%
• 1 month: -4.82%
• 3 months: -6.53%
• 6 months: -23.85%
• Year to date: -28.32%
• 1 year: -26.42%
• 5 years: -98.71%
• 10 years: -99.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Employees: 23